Gilead’s Kite is the current leader in CAR-T, but is looking for ways to stay ahead of competitors and find safer and more effective next-generation therapies.
Gilead’s cell therapy division Kite has signed a deal with a synthetic biology company Refuge Biotechnologies to help it to develop a next generation of CAR-T therapies.
Kite is a leader in the field, marketing Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) for large B-cell lymphoma and follicular
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.
Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.
